

Refocusing

on haemophilia B

Patient-centric approaches to using anti-TFPI



Wednesday, 4 February 2026



16:00 – 17:00 GMT



The Auditorium, Dublin Convention Centre (DCC)
Dublin, Ireland

Agenda



Jerzy Windyga
Poland

Welcome and introduction



Brian O'Mahony
Ireland

Living with haemophilia B: Clinical and life challenges



Ana Boban
Croatia

Anti-TFPI: Changing the landscape of haemophilia B treatment



Ana Boban
Croatia

Navigating clinical scenarios: Leveraging anti-TFPI therapy in haemophilia B management



Jerzy Windyga
Poland

Q&A

This material is intended for the EAHAD congress 2026 only.

This promotional symposium is organised and funded by Novo Nordisk and is intended for healthcare professionals only.

* Arrangements for the meeting comply with the provisions of the Irish Pharmaceutical Healthcare Association Code of Practice for the Pharmaceutical Industry and the Novo Nordisk Business Ethics Code of Conduct.

* Chairperson and speakers will receive financial remuneration from Novo Nordisk Health Care AG.

The Apis bull logo is a registered trademark owned by Novo Nordisk A/S.
© 2025 Novo Nordisk Health Care AG, Zürich, Switzerland.

Month of preparation

December 2025

HQ25HRBD00032